Endocrinology & Metabolic Syndrome
Open Access
ISSN: 2161-1017
+44 1478 350008
ISSN: 2161-1017
+44 1478 350008
David R Owens, Louise Traylor and Wolfgang Landgraf
1Swansea University, UK 2Sanofi US, Inc., USA 3Sanofi Deutschland, Germany
Posters-Accepted Abstracts: Endocrinol Metab Syndr
Aim: Evaluate early (0�¢����12 weeks) and later (12�¢����24 weeks) treatment outcomes after addition of insulin glargine in subjects with type 2 diabetes not achieving glycaemic control with oral anti-diabetes drugs (OADs). Methods: Selected data were pooled from 15 randomized, controlled treat-to-target (fasting plasma glucose <100 mg/dL [<5.6 mmol/L]) trials adding insulin glargine to metformin, a sulphonyl urea, or both. Glycaemic and hypoglycaemia parameters, insulin dose and body weight at weeks 12 and 24 were assessed using individualized subject-level data. Results: Data from 2837 subjects were analysed. HbA1c decreased from 8.8% (73 mmol/mol) at baseline by 1.4% (15mmol/mol) at week 12 and a further 0.2% (2mmol/mol) at Week 24 in the pooled population. Similar reductions were observed across the different treatment groups. HbA1c <7.0% (<53 mmol/mol) was reached by 34.8% of participants at week 12 and an additional 24.3% by week 24. Hypoglycaemia incidence and rates were similar during the early and continued treatment periods across all treatment combinations, but were markedly lower for insulin glargine plus metformin versus the other 2 regimens (P<0.001 for incidence and events rates of overall hypoglycaemia with blood glucose <70 mg/dL during weeks 0�¢����12 and P<0.001 for events rates of overall hypoglycaemia with blood glucose <70 mg/dL during weeks 12�¢����24). Conclusions: Early and sustained glycaemic benefits with a low-risk of hypoglycaemia are observed after initiation of insulin glargine in a pooled type 2 diabetes cohort previously uncontrolled on OADs.
Email: OwensDR@cardiff.ac.uk